NCT04254471 2020-02-05This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in PatientsHaihe Biopharma Co., Ltd.Phase 2/3 Unknown313 enrolled
NCT02109016 2019-07-29A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic AlterationsClovis Oncology, Inc.Phase 2 Terminated18 enrolled